Researchers from Scynexis Inc. have recently presented details on the preclinical characterization of SCY-247, a second-generation triterpenoid with glucan synthase inhibitor activity and intended to be used for the treatment of invasive mucormycosis.
Phosphodiesterase-4 (PDE4) is an intracellular pro-inflammatory enzyme that is considered a therapeutic target in inflammatory disorders such as psoriasis, asthma or ulcerative colitis (UC), among others. Researchers from Palisade Bio Inc. have reported preclinical data on PALI-2108, a PDE4 inhibitor prodrug, in models of UC.
Shares of Corbus Pharmaceuticals Inc. (NASDAQ:CRBP) doubled on opening Jan. 26 and ended the day up a whopping 249% as investors got a look at data from a first-in-human study testing next-generation Nectin-4-targeted antibody-drug conjugate (ADC) CRB-701. Licensed from CSPC Pharmaceutical Group for $7.5 million up front in February 2023, CRB-701 has IND clearance from the U.S. FDA, and Corbus plans to start its own clinical testing in the first quarter of 2024.
The identification of novel immunotherapeutic targets for the treatment of biliary tract cancer (BTC) is still a need. It has been reported that galectin-9 (GAL-9) is expressed in BTC and induces immunosuppressive effects, such as inducing apoptosis in T cells when binding to its receptor TIM-3.
Researchers from Nextcure Inc. have reported the development and preclinical characterization of a novel agonist monoclonal antibody (MAb) against V-set and transmembrane domain containing 1 (VSTM-1).
Analysts from the hosting firm talked up their takeaways on biopharma from the J.P. Morgan (JPM) Healthcare Conference and looked ahead to 2024, anticipating a generally better year than those in the recent past.
Setting the tone for the biopharma industry as it enters a new year, the J.P. Morgan Healthcare Conference (JPM) held each January has once again led to reflections, projections and earnest hopes for improving financial and M&A markets. Despite concerns over valuations, raising money and pricing issues, industry leaders are generally upbeat as the industry moves into 2024. JPM’s Sophie Jones, managing director of health care investment banking, noted in a Jan. 18 webinar sponsored by the Biotechnology Innovation Organization that the conference included more than 700 companies. “It’s morphing now into really the kickoff into everybody’s year.”
There is increasing interest in studying exosome molecules, and particularly long non-coding RNAs (lncRNAs), in the diagnosis of gastric cancer. Microarray analysis was performed from samples obtained from patients with gastric cancer who underwent endoscopic resection.
Tough times can create great companies if they can navigate the turbulence, a panel of biopharma executives and academics told attendees at the Wuxi Global Forum 2024. Companies must learn how to endure bad periods and thrive during the good times, said Mathai Mammen, CEO of Fogpharma Inc., because those disparate financial and scientific cycles will never go away. Right now, the money part is tough, but the science is thriving
RSS
